Summary:
A PHASE 1, DOUBLE-BLIND, PLACEBOCONTROLLED
CROSSOVER STUDY OF SAGE-718
USING A KETAMINE CHALLENGE, TO EVALUATE
THE ELECTROPHYSIOLOGY, SAFETY,
TOLERABILITY, AND PHARMACOKINETICS IN
HEALTHY SUBJECTS
Qualified Participants Must:
• Patient is 18 to 65 years of age
Qualified Participants May Receive:
Compesation for time and travel